Spaces:

ferferefer
/

preserflo_slides

Running

App Files Files Community

ferferefer commited on 10 days ago

Commit

f928a6c

verified ·

1 Parent(s): f688d5f

Delete index.html

Browse files

Files changed (1) hide show

index.html +0 -393

index.html DELETED Viewed

@@ -1,393 +0,0 @@
-<!DOCTYPE html>
-<html lang="en">
-<head>
-    <meta charset="UTF-8">
-    <meta name="viewport" content="width=device-width, initial-scale=1.0">
-    <title>Preserflo™ MicroShunt Presentation</title>
-    <!-- Tailwind CSS -->
-    <script src="https://cdn.tailwindcss.com"></script>
-    <!-- reveal.js -->
-    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/reveal.js/4.6.1/reveal.min.css">
-    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/reveal.js/4.6.1/theme/sky.min.css" id="theme">
-    <!-- Font Awesome Icons -->
-    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/6.4.0/css/all.min.css">
-    <style>
-        /* Custom Styles for Professional Look */
-        .reveal .slides section {
-            text-align: left; /* Default text alignment */
-            display: flex !important;
-            flex-direction: column;
-            justify-content: center; /* Center content vertically */
-            align-items: center; /* Center content horizontally */
-            min-height: 700px; /* Consistent slide height */
-            padding: 40px; /* Padding around slide content */
-            box-sizing: border-box;
-        }
-        .reveal .slide-content {
-            display: flex;
-            align-items: center; /* Vertically align items in the flex container */
-            justify-content: space-between; /* Space out text and visual content */
-            width: 100%; /* Full width within padding */
-            max-width: 1100px; /* Max width for content */
-            margin: auto; /* Center the content container */
-        }
-         .reveal .slide-content-vertical { /* For layouts where visual is above/below text */
-             flex-direction: column;
-             text-align: center;
-         }
-        .reveal .text-content {
-            flex: 1; /* Allow text content to take available space */
-            padding-right: 30px; /* Space between text and visual */
-            max-width: 60%; /* Limit text width for readability */
-        }
-         .reveal .text-content-full { /* For slides primarily text */
-             flex: 1;
-             width: 100%;
-             max-width: 900px; /* Wider max-width for text-heavy slides */
-         }
-        .reveal .visual-content {
-            flex-shrink: 0; /* Prevent visual content from shrinking */
-            width: 35%; /* Adjust visual content width */
-            text-align: center; /* Center images/icons */
-        }
-         .reveal .visual-content-full { /* For title slide visual */
-             width: auto;
-             margin-top: 2rem;
-         }
-         .reveal .visual-content i { /* Icon styling */
-            font-size: 7rem; /* Standard icon size */
-            color: #0ea5e9; /* Tailwind sky-500 */
-            margin-bottom: 1rem;
-         }
-         .reveal img.slide-image {
-             max-width: 100%;
-             max-height: 350px; /* Limit image height */
-             object-fit: contain; /* Ensure image scales nicely */
-             border-radius: 8px; /* Slightly rounded corners */
-             box-shadow: 0 4px 8px rgba(0,0,0,0.1); /* Subtle shadow */
-         }
-        .reveal h1 {
-             color: #ffffff; /* White for title slide */
-             font-size: 3.5em;
-             font-weight: bold;
-             margin-bottom: 0.5em;
-         }
-        .reveal h2 {
-            color: #0284c7; /* Tailwind sky-600 */
-            font-size: 2.5em;
-            font-weight: bold;
-            margin-bottom: 1em;
-            text-align: center;
-             width: 100%;
-        }
-         .reveal h3 {
-             color: #0369a1; /* Tailwind sky-700 */
-             font-size: 1.6em;
-             font-weight: bold;
-             margin-bottom: 0.8em;
-         }
-          .reveal h4 {
-              font-size: 1.2em;
-              color: #075985; /* Tailwind sky-800 */
-              font-weight: bold;
-              margin-bottom: 0.5em;
-          }
-        .reveal ul {
-            list-style: none;
-            padding-left: 0;
-        }
-        .reveal ul li {
-            font-size: 1.0em;
-            margin-bottom: 0.7em;
-            padding-left: 2em;
-            position: relative;
-            line-height: 1.4;
-        }
-        .reveal ul li::before {
-            content: "\f00c"; /* Font Awesome check icon */
-            font-family: 'Font Awesome 6 Free';
-            font-weight: 900;
-            color: #34d399; /* Tailwind emerald-400 */
-            position: absolute;
-            left: 0;
-            top: 4px;
-            font-size: 0.9em;
-        }
-         .reveal p {
-             font-size: 1.05em;
-             line-height: 1.5;
-             margin-bottom: 1em;
-         }
-        .reveal .citation {
-             font-size: 0.65em;
-             color: #6b7280; /* Tailwind gray-500 */
-             margin-top: 15px;
-             display: block;
-             text-align: right;
-        }
-         .reveal .slide-background-content { /* Default slide background */
-             background-color: #f0f9ff; /* Tailwind sky-50 */
-         }
-         /* Specific Slide Backgrounds */
-         .reveal section[data-background-color="#0ea5e9"] h1,
-         .reveal section[data-background-color="#0ea5e9"] p {
-             color: white;
-         }
-         .reveal section[data-background-color="#0ea5e9"] i {
-             color: white;
-         }
-         .comparison-grid {
-             display: grid;
-             grid-template-columns: 1fr 1fr;
-             gap: 20px;
-             width: 100%;
-         }
-          .comparison-grid h4 {
-              text-align: center;
-              margin-bottom: 1em;
-          }
-           .comparison-grid ul li::before {
-                top: 6px; /* Adjust icon position slightly */
-           }
-    </style>
-</head>
-<body>
-    <div class="reveal">
-        <div class="slides">
-            <!-- Slide 1: Title -->
-            <section data-background-color="#0ea5e9">
-                 <div class="slide-content-vertical">
-                    <h1>The Preserflo™ MicroShunt</h1>
-                    <p class="text-2xl font-light">A Modern Surgical Solution for Glaucoma Management</p>
-                    <div class="visual-content-full">
-                        <i class="fas fa-eye text-7xl"></i>
-                    </div>
-                 </div>
-            </section>
-            <!-- Slide 2: What is Glaucoma? -->
-            <section class="slide-background-content">
-                 <h2>Understanding Glaucoma</h2>
-                 <div class="slide-content">
-                     <div class="text-content">
-                         <h3>The Challenge of IOP</h3>
-                         <p>Glaucoma is a group of eye diseases often characterized by elevated Intraocular Pressure (IOP). [3, 6] This pressure rises when the eye's natural fluid (aqueous humor) doesn't drain properly due to blockage. [3, 8]</p>
-                         <p>Sustained high IOP damages the optic nerve, responsible for sending visual information to the brain, which can lead to permanent vision loss. [2, 3, 6] The core goal of glaucoma treatment is effectively lowering IOP to preserve sight. [1, 7]</p>
-                          <span class="citation">Sources: [1], [2], [3], [6], [7], [8]</span>
-                     </div>
-                     <div class="visual-content">
-                         <i class="fas fa-tachometer-alt-fast"></i>
-                         <p class="mt-2 text-sm text-gray-600">[Placeholder: Diagram illustrating increased IOP and potential optic nerve damage]</p>
-                     </div>
-                 </div>
-            </section>
-            <!-- Slide 3: What is Preserflo? -->
-            <section class="slide-background-content">
-                <h2>Introducing Preserflo™ MicroShunt</h2>
-                <div class="slide-content">
-                    <div class="text-content">
-                        <h3>Device Overview</h3>
-                        <p>The Preserflo™ MicroShunt is a tiny, soft, flexible tube, about 8-8.5mm long, designed specifically for glaucoma surgery. [2, 3, 7, 21] Its primary function is to safely lower eye pressure. [1, 2, 7]</p>
-                        <p>It's crafted from SIBS (poly(styrene-block-isobutylene-block-styrene)), a highly biocompatible and inert material also used in coronary stents. [1, 2, 7, 24] This minimizes inflammation and the risk of rejection or degradation. [2, 3, 7, 23]</p>
-                         <p>Features include stabilizing fins and a precise lumen diameter (70µm internal) designed to control fluid outflow. [1, 8, 13, 22] It is non-metallic and MRI/CT safe. [2, 3, 7]</p>
-                         <span class="citation">Sources: [1], [2], [3], [7], [8], [13], [21], [22], [23], [24]</span>
-                    </div>
-                     <div class="visual-content">
-                         <!-- Placeholder for actual image -->
-                         <img src="https://via.placeholder.com/300x200.png?text=Preserflo+MicroShunt+Device" alt="Preserflo MicroShunt Device" class="slide-image">
-                         <p class="mt-2 text-sm text-gray-600">[Placeholder: Actual image of the Preserflo MicroShunt]</p>
-                     </div>
-                </div>
-            </section>
-            <!-- Slide 4: How it Works -->
-            <section class="slide-background-content">
-                 <h2>Mechanism of Action</h2>
-                 <div class="slide-content">
-                     <div class="visual-content">
-                          <!-- Placeholder for actual image/diagram -->
-                         <img src="https://via.placeholder.com/300x300.png?text=Shunt+Placement+Diagram" alt="Diagram showing Preserflo placement and bleb formation" class="slide-image">
-                         <p class="mt-2 text-sm text-gray-600">[Placeholder: Diagram showing shunt placement and fluid flow to bleb]</p>
-                     </div>
-                    <div class="text-content pl-8">
-                         <h3>Creating a New Pathway</h3>
-                         <p>The MicroShunt acts as a bypass for the eye's natural, obstructed drainage system. [3, 6, 7, 13]</p>
-                         <p>Implanted via an 'ab externo' approach, one end sits in the anterior chamber, accessing the excess aqueous humor. [1, 4, 6, 8] The other end channels this fluid out of the eye, directing it into the subconjunctival/sub-Tenon space. [2, 4, 8, 23]</p>
-                         <p>This drained fluid forms a small, low-profile reservoir called a 'bleb' under the upper eyelid, where it is safely absorbed by surrounding tissues into the bloodstream, thus reducing IOP. [2, 3, 5, 7]</p>
-                         <span class="citation">Sources: [1], [2], [3], [4], [5], [6], [7], [8], [13], [23]</span>
-                    </div>
-                </div>
-            </section>
-            <!-- Slide 5: Indications -->
-            <section class="slide-background-content">
-                 <h2>Who is a Candidate for Preserflo?</h2>
-                 <div class="slide-content">
-                     <div class="text-content">
-                        <h3>Patient Suitability</h3>
-                         <ul>
-                             <li>Primarily indicated for Primary Open-Angle Glaucoma (POAG), including subtypes like pseudoexfoliation and pigmentary glaucoma. [1, 11, 18]</li>
-                             <li>Patients whose IOP is not adequately controlled with maximal tolerated medications or laser therapy. [2, 7, 8, 11]</li>
-                             <li>Individuals experiencing glaucoma progression that necessitates surgical intervention. [6, 8, 11]</li>
-                            <li>Those who have difficulty with adherence to, or intolerance of, eye drop regimens. [7, 11]</li>
-                            <li>May be considered for moderate-to-advanced glaucoma stages. [3, 10]</li>
-                         </ul>
-                        <p>Not suitable for angle-closure glaucoma, active infection, or severe dry eye. [1, 8, 13]</p>
-                         <span class="citation">Sources: [1], [2], [3], [6], [7], [8], [10], [11], [13], [18]</span>
-                     </div>
-                     <div class="visual-content">
-                        <i class="fas fa-user-check"></i>
-                        <p class="mt-2 text-sm text-gray-600">[Placeholder: Image representing patient consultation or eye exam]</p>
-                     </div>
-                 </div>
-            </section>
-            <!-- Slide 6: The Procedure -->
-            <section class="slide-background-content">
-                 <h2>The Implantation Procedure</h2>
-                 <div class="slide-content">
-                     <div class="visual-content">
-                         <i class="fas fa-user-md"></i>
-                         <p class="mt-2 text-sm text-gray-600">[Placeholder: Image or simple graphic of surgical setting/instruments]</p>
-                     </div>
-                     <div class="text-content pl-8">
-                        <h3>Surgical Steps</h3>
-                         <ul>
-                             <li>Typically performed as an outpatient (day surgery) procedure. [2, 4, 6, 13]</li>
-                             <li>Surgery duration is often around 30-45 minutes. [2, 21, 26]</li>
-                             <li>Anesthesia options include local (injection or drops) or general anesthesia. [1, 2, 19]</li>
-                             <li>Utilizes an 'ab externo' technique, familiar to glaucoma surgeons. [1, 22, 23]</li>
-                             <li>Involves a conjunctival incision and careful dissection. [1, 2]</li>
-                             <li>Mitomycin-C (MMC), an anti-scarring agent, is applied to enhance long-term success. [1, 2, 21, 17]</li>
-                             <li>The MicroShunt is inserted, and the conjunctiva is closed, often with dissolvable stitches. [2, 3]</li>
-                         </ul>
-                        <span class="citation">Sources: [1], [2], [3], [4], [6], [13], [17], [19], [21], [22], [23], [26]</span>
-                     </div>
-                 </div>
-            </section>
-            <!-- Slide 7: Benefits -->
-            <section class="slide-background-content">
-                 <h2>Benefits of Preserflo™ MicroShunt</h2>
-                <div class="slide-content">
-                    <div class="text-content">
-                         <h3>Key Advantages</h3>
-                         <ul>
-                             <li><strong>Significant IOP Lowering:</strong> Proven to effectively reduce eye pressure, with studies showing sustained results. [1, 4, 7, 20, 26]</li>
-                             <li><strong>Less Dependence on Drops:</strong> Substantially reduces or eliminates the need for daily glaucoma medications for many patients. [2, 3, 6, 7, 8, 13, 16, 17, 20]</li>
-                             <li><strong>Less Invasive Nature:</strong> Compared to trabeculectomy, the procedure is generally considered less invasive. [4, 6, 12, 13, 19, 23, 26]</li>
-                             <li><strong>Favorable Safety Profile:</strong> Designed to minimize risks, with studies indicating lower rates of certain complications like hypotony vs. trabeculectomy. [4, 8, 9, 13, 19, 22, 26, 29]</li>
-                             <li><strong>Potentially Faster Recovery:</strong> Patients may experience quicker visual recovery and return to normal activities. [6, 19, 22, 26]</li>
-                              <li><strong>Predictability:</strong> Aims for more predictable IOP outcomes compared to trabeculectomy. [22]</li>
-                         </ul>
-                         <span class="citation">Sources: [1-4, 6-9, 12, 13, 16, 17, 19, 20, 22, 23, 26, 29]</span>
-                     </div>
-                    <div class="visual-content">
-                         <i class="fas fa-shield-check"></i>
-                          <p class="mt-2 text-sm text-gray-600">[Placeholder: Icon or graphic representing benefits/improvement]</p>
-                    </div>
-                 </div>
-            </section>
-            <!-- Slide 8: Preserflo vs. Trabeculectomy -->
-            <section class="slide-background-content">
-                 <h2>Preserflo vs. Trabeculectomy: Comparison</h2>
-                 <div class="text-content-full">
-                     <h3>Why Preserflo Might Be Preferred</h3>
-                     <div class="comparison-grid mt-4">
-                         <div>
-                             <h4 class="text-sky-700">Preserflo MicroShunt</h4>
-                             <ul>
-                                 <li>Standardized device & procedure [1, 22]</li>
-                                 <li>Less invasive surgical technique [19, 23, 26]</li>
-                                 <li>Significantly lower risk of hypotony [5, 25, 28, 29]</li>
-                                 <li>Potentially fewer complications overall [5, 13, 26]</li>
-                                 <li>Fewer postoperative interventions (needling, etc.) in some studies [12, 23, 25]</li>
-                                 <li>Faster visual recovery suggested [19, 22, 26]</li>
-                                 <li>Better visual field preservation reported [5, 29]</li>
-                                 <li>More posterior bleb formation [15, 23]</li>
-                             </ul>
-                         </div>
-                         <div>
-                             <h4 class="text-sky-700">Trabeculectomy</h4>
-                             <ul>
-                                 <li>Long-established "gold standard" [12, 23]</li>
-                                 <li>Requires manual scleral flap creation [14, 22]</li>
-                                 <li>Higher incidence of early hypotony [25, 28, 29]</li>
-                                 <li>Can have more early/late complications [5]</li>
-                                 <li>Often needs more intensive post-op management [12, 23, 25]</li>
-                                  <li>May achieve slightly lower IOP in some studies [14, 22, 29]</li>
-                                  <li>More anterior bleb [15, 23]</li>
-                             </ul>
-                         </div>
-                     </div>
-                     <p class="mt-6 text-center">Preserflo offers a balance of effective IOP control with an improved safety profile and potentially simpler recovery, making it an attractive alternative, especially where hypotony is a concern. [12, 19, 22, 25, 29]</p>
-                     <span class="citation">Sources: [1, 5, 12-15, 19, 22, 23, 25, 26, 28, 29]</span>
-                </div>
-            </section>
-            <!-- Slide 9: Safety & Considerations -->
-            <section class="slide-background-content">
-                <h2>Safety & Important Considerations</h2>
-                 <div class="slide-content">
-                    <div class="text-content">
-                         <h3>Potential Risks</h3>
-                         <p>While designed for safety, potential surgical risks include:</p>
-                         <ul>
-                             <li><strong>IOP Fluctuations:</strong> Pressure may become too low (hypotony, often transient) or remain too high (hypertension), potentially requiring management. [1, 2, 3, 9, 13, 20, 21, 28]</li>
-                             <li><strong>Bleeding (Hyphema):</strong> Usually minimal and resolves spontaneously; severe bleeding is rare. [2, 7, 9, 21]</li>
-                             <li><strong>Infection (Endophthalmitis):</strong> A rare but serious lifelong risk associated with filtering blebs. [2, 3, 9, 13]</li>
-                             <li><strong>Need for Re-intervention:</strong> Scarring or blockage may necessitate procedures like bleb needling or surgical revision. [1, 2, 3, 16, 20, 28, 29]</li>
-                             <li><strong>Other Potential Issues:</strong> Transient blurred vision, shallow anterior chamber, choroidal effusion/detachment, cataract progression, rare shunt exposure or migration. [1, 2, 3, 9, 20]</li>
-                         </ul>
-                         <p>Regular post-operative monitoring is crucial for optimal outcomes. [2, 3, 5]</p>
-                         <span class="citation">Sources: [1-3, 5, 7, 9, 13, 16, 20, 21, 28, 29]</span>
-                     </div>
-                     <div class="visual-content">
-                         <i class="fas fa-exclamation-triangle text-yellow-500"></i>
-                         <p class="mt-2 text-sm text-gray-600">[Placeholder: Icon representing caution or safety check]</p>
-                     </div>
-                </div>
-            </section>
-            <!-- Slide 10: Conclusion -->
-             <section class="slide-background-content">
-                <h2>Conclusion: Preserflo™ in Modern Glaucoma Care</h2>
-                 <div class="slide-content">
-                     <div class="visual-content">
-                        <i class="fas fa-graduation-cap"></i>
-                        <p class="mt-2 text-sm text-gray-600">[Placeholder: Graphic representing innovation or forward-thinking]</p>
-                     </div>
-                     <div class="text-content pl-8">
-                         <h3>Key Takeaways</h3>
-                         <p>The Preserflo™ MicroShunt is an innovative surgical device offering a significant evolution in glaucoma treatment. [19]</p>
-                         <ul>
-                             <li>Provides effective and sustained IOP reduction, comparable to trabeculectomy in many cases, while reducing reliance on eye drops. [1, 12, 14, 17, 20]</li>
-                             <li>Features an enhanced safety profile, notably lower rates of hypotony and potentially fewer overall complications compared to trabeculectomy. [1, 9, 19, 23, 28, 29]</li>
-                             <li>Offers potential benefits of a less invasive procedure, faster recovery, and simpler post-operative management. [12, 19, 23, 25, 26]</li>
-                         </ul>
-                         <p>It represents a valuable and reliable option for surgeons and patients seeking effective IOP control with improved safety and predictability in the management of open-angle glaucoma. [1, 19, 22, 23]</p>
-                         <span class="citation">Sources: [1], [9], [12], [14], [17], [19], [20], [22], [23], [25], [26], [28], [29]</span>
-                    </div>
-                 </div>
-            </section>
-        </div>
-    </div>
-    <!-- reveal.js -->
-    <script src="https://cdnjs.cloudflare.com/ajax/libs/reveal.js/4.6.1/reveal.min.js"></script>
-    <script src="https://cdnjs.cloudflare.com/ajax/libs/reveal.js/4.6.1/plugin/notes/notes.min.js"></script>
-    <script src="https://cdnjs.cloudflare.com/ajax/libs/reveal.js/4.6.1/plugin/markdown/markdown.min.js"></script>
-    <script src="https://cdnjs.cloudflare.com/ajax/libs/reveal.js/4.6.1/plugin/highlight/highlight.min.js"></script>
-    <script>
-        Reveal.initialize({
-            hash: true, // Enables deep linking to slides
-            plugins: [ RevealMarkdown, RevealHighlight, RevealNotes ] // Basic plugins
-        });
-    </script>
-</body>
-</html>